Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as forodesine hydrochloride, forodesine hydrochloride (BCX-1777), forodesine HCl
forodesine · 8 trials · 7 indications
| Name | Type | Description |
|---|---|---|
| forodesine HCl | DRUG | 2 x 100mg capsules daily |
| Forodesine 200 mg | DRUG | 2 x 100mg tablets once daily |
| forodesine hydrochloride (BCX-1777) | DRUG | experimental, forodesine oral dose 200 mg administered daily. |
| forodesine hydrochloride | DRUG | - |
Inclusion Criteria: 1. Age 18 years and older 2. Diagnosis of CLL established by peripheral blood and/or bone marrow examination and using the standard diagnostic criteria. 3. Subjects with Rai stage III or IV, or earlier stage requiring therapy as determined by the 1996 National Cancer Institute -...
Top 1 of 2 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Incyte Corporation | INCY | 2 | PHASE2 | Ruxolitinib |
Forodesine is an investigational small molecule drug developed by BioCryst Pharmaceuticals, Inc. (ticker BCRX) for certain blood cancers. It has been studied in B-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, cutaneous T-cell lymphoma, and other leukemias and lymphomas. It is not approved and remains in clinical development.
Forodesine has been studied in several hematologic cancers, including B-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, cutaneous T-cell lymphoma, and other leukemia and lymphoma indications. These studies were conducted in adults aged 18 years and older. Forodesine is investigational and is not an approved treatment for any indication.
Forodesine targets purine nucleoside phosphorylase, or PNP, and acts as an inhibitor of that enzyme. PNP is involved in purine metabolism, and inhibiting it is the intended mechanism of action for this small molecule in lymphoid malignancies. The drug was designed to interfere with PNP activity in cancer cells.
Forodesine is developed by BioCryst Pharmaceuticals, Inc., which trades under the ticker BCRX. BioCryst is the company associated with the forodesine hydrochloride compound, also referred to as BCX-1777, across its clinical development programs in leukemia and lymphoma.
Forodesine is in Phase 1 development and is investigational. It has not been approved by the FDA for any indication. Clinical work has included Phase 1 and Phase 2 studies, and no trials are currently active. The completed studies enrolled a total of 144 participants across the programs.
Completed forodesine trials include NCT00640523 in chronic lymphocytic leukemia, NCT00501735 in cutaneous T-cell lymphoma, NCT00289562 in B-cell acute lymphoblastic leukemia, and NCT00289549 in fludarabine-refractory chronic lymphocytic leukemia. These studies were conducted across the United States, Australia, and several European countries. All are listed as completed.
Yes, forodesine hydrochloride is the salt form of forodesine and is also known as BCX-1777. Other names used for this asset include forodesine HCl and Forodesine 200 mg. These names refer to the same BioCryst Pharmaceuticals compound studied in leukemia and lymphoma trials.